Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021.
This nationwide population-based cohort study evaluated cancer risk in 2,150 patients with immunoglobulin G4-related dis...
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
- Post category:Hematologic Cancers
- Reading time:1 min read
This publication reviews the advancements in frontline treatment for newly diagnosed, transplant-eligible multiple myelo...
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
- Post category:Hematologic Cancers
- Reading time:1 min read
This phase 3 GEM12 trial evaluated long-term outcomes of autologous stem cell transplantation (ASCT) conditioning with b...
Treatment of transplant-ineligible multiple myeloma.
- Post category:Hematologic Cancers
- Reading time:1 min read
This publication reviews the evolving treatment landscape for transplant-ineligible multiple myeloma (MM) patients. It h...
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).
- Post category:Hematologic Cancers
- Reading time:1 min read
This randomized study evaluated pomalidomide, cyclophosphamide, dexamethasone (PCD) versus pomalidomide and dexamethason...
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study evaluates the real-world efficacy and safety of two CAR T-cell therapies, idecabtagene vicleucel (ide-cel) an...